Market Cap 3.69M
Revenue (ttm) 90,000.00
Net Income (ttm) -13.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -15,511.11%
Debt to Equity Ratio 0.10
Volume 1,926,000
Avg Vol 24,367,020
Day's Range N/A - N/A
Shares Out 14.56M
Stochastic %K 74%
Beta 1.20
Analysts Sell
Price Target $5.25

Company Profile

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon produ...

Industry: Biotechnology
Sector: Healthcare
Phone: 352 448 7797
Fax: 352 480 4620
Address:
2117 SW Highway 484, Ocala, United States
TheLionofwallstreet
TheLionofwallstreet Aug. 3 at 3:49 PM
$AIM great news! Sucks the company has been dragged through so much mud to get to this point. Lets see what happens. I'll be lucky one day to break even while others will become rich. The bright side is that many families will benefit from ampligens help. That is priceless. Fck cncer
0 · Reply
uuddlrlr
uuddlrlr Aug. 3 at 3:28 PM
$AIM "Analysis of the DURIPANC Overall Survival Endpoint is expected to begin in June 2027, or 49 weeks after this final subject received their first dose. DURIPANC’s Secondary Endpoints include Overall Survival – the gold standard in oncology trials – as well as progression-free survival and a completed immune profiling analysis that could potentially help identify subsets of future pancreatic cancer patients likely to experience the best clinical benefit and overall survival results, which could be critical to the design of a pivotal Phase 3 clinical trial." Good update but timeline to Phase 3 launch and results appears far off. AIM needs to find some funding that is not dilution.
2 · Reply
AIM_ImmunoTech
AIM_ImmunoTech Aug. 3 at 1:26 PM
$AIM Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point https://aimimmuno.com/aim-immunotech-ahead-of-schedule-on-last-dose-duripanc-critical-clinical-inflection-point/
0 · Reply
focafoca99
focafoca99 Aug. 3 at 12:45 PM
$AIM hit a Phase 2 milestone early as the last patient got the final dose in its DURIPANC pancreatic cancer trial. https://www.rapidticker.com/news/aim-aim-immunotech-ahead-of-schedule-c3d0c1
0 · Reply
MrTicker
MrTicker Aug. 3 at 12:42 PM
$AIM AIM ImmunoTech Inc. (AIM) ("AIM" or the "Company") today announced that the final subject has received their last dose of Ampligen® (rintatolimod) under the study protocol, reaching this milestone ahead of schedule in the Phase 2 DURIPANC clinical trial evaluating Ampligen in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of metastatic pancreatic cancer
0 · Reply
MrTicker
MrTicker Aug. 3 at 12:41 PM
$AIM AIM ImmunoTech Announces Final Subjects Receives Last Dose Of Ampligen Under Study Protocol In Phase 2 DURIPANC Clinical Study BENZINGA 7:41 AM ET 8/3/2026
0 · Reply
Friends4eva
Friends4eva Jul. 31 at 3:44 PM
$AIM $SPY $SOXS I'm going to guess he had a hedge fund that didn't hedge.
1 · Reply
FBP
FBP Jul. 31 at 3:42 PM
This young closeted psychopath brat looking villain is straight out of a movie! $AIM $SPY $SOXS 👀👀
2 · Reply
Wizardof0z
Wizardof0z Jul. 31 at 3:33 PM
$AIM $CIGL $DFNS $SBEV ok thanks for letting us know now leave
0 · Reply
Aklim72
Aklim72 Jul. 31 at 3:31 PM
$DFNS I would rather take my chances on $SBEV $AIM $CIGL
0 · Reply
Latest News on AIM
AIM ImmunoTech Proxy statement: Proxy filing

Jun 25, 2026, 8:00 AM EDT - 5 weeks ago

AIM ImmunoTech Proxy statement: Proxy filing


AIM ImmunoTech Registration statement: Registration filing

Jun 18, 2026, 8:00 AM EDT - 6 weeks ago

AIM ImmunoTech Registration statement: Registration filing


AIM ImmunoTech Proxy statement: Proxy filing

Jun 15, 2026, 8:00 AM EDT - 7 weeks ago

AIM ImmunoTech Proxy statement: Proxy filing


AIM ImmunoTech Inc trading resumes

2026-06-09T13:50:10.000Z - 2 months ago

AIM ImmunoTech Inc trading resumes


AIM ImmunoTech announces $2.65M registered direct offering

2026-06-09T13:41:34.000Z - 2 months ago

AIM ImmunoTech announces $2.65M registered direct offering


AIM ImmunoTech Inc trading halted, news pending

2026-06-09T13:29:35.000Z - 2 months ago

AIM ImmunoTech Inc trading halted, news pending


AIM ImmunoTech Registration statement: Registration filing

Jun 8, 2026, 8:00 AM EDT - 2 months ago

AIM ImmunoTech Registration statement: Registration filing


3 Penny Stocks Drawing Market Attention, 6/2/26

2026-06-02T17:36:51.000Z - 2 months ago

3 Penny Stocks Drawing Market Attention, 6/2/26

ANY HKIT


AIM ImmunoTech Inc trading resumes

2026-05-20T19:20:11.000Z - 2 months ago

AIM ImmunoTech Inc trading resumes


AIM ImmunoTech announces $2.4M registered direct offering

2026-05-20T19:10:27.000Z - 2 months ago

AIM ImmunoTech announces $2.4M registered direct offering


AIM ImmunoTech Inc trading halted, news pending

2026-05-20T19:00:12.000Z - 2 months ago

AIM ImmunoTech Inc trading halted, news pending


CMMI Institute Completes Pilot for New AI Maturity (AIM) Framework

May 19, 2026, 11:41 AM EDT - 2 months ago

CMMI Institute Completes Pilot for New AI Maturity (AIM) Framework


AIM ImmunoTech Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 2 months ago

AIM ImmunoTech Quarterly report: Q1 2026


AIM ImmunoTech Transcript: Virtual Investor Closing Bell

Apr 16, 2026, 4:00 PM EDT - 3 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell


AIM ImmunoTech Provides Routine Update on Annual Filings

Apr 13, 2026, 6:00 PM EDT - 4 months ago

AIM ImmunoTech Provides Routine Update on Annual Filings


AIM ImmunoTech Annual report: Q4 2025

Mar 27, 2026, 4:00 PM EDT - 4 months ago

AIM ImmunoTech Annual report: Q4 2025


Biotech Alert: Searches spiking for these stocks today

2026-03-20T14:55:28.000Z - 4 months ago

Biotech Alert: Searches spiking for these stocks today


Why Is AIM ImmunoTech Stock (AIM) Up Today?

2026-03-18T13:47:09.000Z - 4 months ago

Why Is AIM ImmunoTech Stock (AIM) Up Today?


AIM announces approval of patent for Ampligen in Japan

2026-03-18T12:51:46.000Z - 4 months ago

AIM announces approval of patent for Ampligen in Japan


AIM ImmunoTech Announces Closing of its Rights Offering

Mar 6, 2026, 7:00 PM EST - 5 months ago

AIM ImmunoTech Announces Closing of its Rights Offering


Biotech Alert: Searches spiking for these stocks today

2026-03-04T15:25:35.000Z - 5 months ago

Biotech Alert: Searches spiking for these stocks today


AIM ImmunoTech announces preliminary results of rights offering

2026-03-04T14:05:33.000Z - 5 months ago

AIM ImmunoTech announces preliminary results of rights offering


AIM ImmunoTech extends subscription period of rights offering

2026-02-25T14:19:06.000Z - 5 months ago

AIM ImmunoTech extends subscription period of rights offering


AIM ImmunoTech Transcript: Virtual Investor Closing Bell

Feb 19, 2026, 4:00 PM EST - 5 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell


AIM ImmunoTech Transcript: Corporate Connect Webinar Series

Feb 11, 2026, 1:40 PM EST - 6 months ago

AIM ImmunoTech Transcript: Corporate Connect Webinar Series


AIM ImmunoTech Announces Commencement of Rights Offering

Feb 11, 2026, 8:30 AM EST - 6 months ago

AIM ImmunoTech Announces Commencement of Rights Offering


AIM ImmunoTech Registration statement: Registration Filing

Feb 10, 2026, 7:00 AM EST - 6 months ago

AIM ImmunoTech Registration statement: Registration Filing


AIM ImmunoTech Slides: Corporate presentation

Feb 4, 2026, 7:00 AM EST - 6 months ago

AIM ImmunoTech Slides: Corporate presentation


AIM ImmunoTech Registration statement: Registration Filing

Jan 29, 2026, 7:00 AM EST - 6 months ago

AIM ImmunoTech Registration statement: Registration Filing


AIM ImmunoTech Registration statement: Registration filing

Jan 23, 2026, 7:00 AM EST - 6 months ago

AIM ImmunoTech Registration statement: Registration filing


AIM ImmunoTech Transcript: AGM 2025

Dec 16, 2025, 11:00 AM EST - 8 months ago

AIM ImmunoTech Transcript: AGM 2025


AIM ImmunoTech Transcript: Virtual Investor Closing Bell Series

Dec 4, 2025, 4:00 PM EST - 8 months ago

AIM ImmunoTech Transcript: Virtual Investor Closing Bell Series


AIM ImmunoTech Quarterly report: Q3 2025

Nov 17, 2025, 4:00 PM EST - 9 months ago

AIM ImmunoTech Quarterly report: Q3 2025


AIM ImmunoTech Proxy statement: Proxy Filing

Oct 29, 2025, 8:30 AM EDT - 9 months ago

AIM ImmunoTech Proxy statement: Proxy Filing


AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

Oct 20, 2025, 9:15 AM EDT - 10 months ago

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit


AIM ImmunoTech Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

AIM ImmunoTech Quarterly report: Q2 2025


AIM ImmunoTech Earnings release: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

AIM ImmunoTech Earnings release: Q2 2025


AIM ImmunoTech Resumes Trading on NYSE American

Jun 17, 2025, 8:55 AM EDT - 1 year ago

AIM ImmunoTech Resumes Trading on NYSE American


AIM ImmunoTech Announces 1-for-100 Reverse Stock Split

Jun 11, 2025, 4:15 PM EDT - 1 year ago

AIM ImmunoTech Announces 1-for-100 Reverse Stock Split


AIM ImmunoTech Quarterly report: Q1 2025

May 15, 2025, 4:00 PM EDT - 1 year ago

AIM ImmunoTech Quarterly report: Q1 2025


TheLionofwallstreet
TheLionofwallstreet Aug. 3 at 3:49 PM
$AIM great news! Sucks the company has been dragged through so much mud to get to this point. Lets see what happens. I'll be lucky one day to break even while others will become rich. The bright side is that many families will benefit from ampligens help. That is priceless. Fck cncer
0 · Reply
uuddlrlr
uuddlrlr Aug. 3 at 3:28 PM
$AIM "Analysis of the DURIPANC Overall Survival Endpoint is expected to begin in June 2027, or 49 weeks after this final subject received their first dose. DURIPANC’s Secondary Endpoints include Overall Survival – the gold standard in oncology trials – as well as progression-free survival and a completed immune profiling analysis that could potentially help identify subsets of future pancreatic cancer patients likely to experience the best clinical benefit and overall survival results, which could be critical to the design of a pivotal Phase 3 clinical trial." Good update but timeline to Phase 3 launch and results appears far off. AIM needs to find some funding that is not dilution.
2 · Reply
AIM_ImmunoTech
AIM_ImmunoTech Aug. 3 at 1:26 PM
$AIM Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point https://aimimmuno.com/aim-immunotech-ahead-of-schedule-on-last-dose-duripanc-critical-clinical-inflection-point/
0 · Reply
focafoca99
focafoca99 Aug. 3 at 12:45 PM
$AIM hit a Phase 2 milestone early as the last patient got the final dose in its DURIPANC pancreatic cancer trial. https://www.rapidticker.com/news/aim-aim-immunotech-ahead-of-schedule-c3d0c1
0 · Reply
MrTicker
MrTicker Aug. 3 at 12:42 PM
$AIM AIM ImmunoTech Inc. (AIM) ("AIM" or the "Company") today announced that the final subject has received their last dose of Ampligen® (rintatolimod) under the study protocol, reaching this milestone ahead of schedule in the Phase 2 DURIPANC clinical trial evaluating Ampligen in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of metastatic pancreatic cancer
0 · Reply
MrTicker
MrTicker Aug. 3 at 12:41 PM
$AIM AIM ImmunoTech Announces Final Subjects Receives Last Dose Of Ampligen Under Study Protocol In Phase 2 DURIPANC Clinical Study BENZINGA 7:41 AM ET 8/3/2026
0 · Reply
Friends4eva
Friends4eva Jul. 31 at 3:44 PM
$AIM $SPY $SOXS I'm going to guess he had a hedge fund that didn't hedge.
1 · Reply
FBP
FBP Jul. 31 at 3:42 PM
This young closeted psychopath brat looking villain is straight out of a movie! $AIM $SPY $SOXS 👀👀
2 · Reply
Wizardof0z
Wizardof0z Jul. 31 at 3:33 PM
$AIM $CIGL $DFNS $SBEV ok thanks for letting us know now leave
0 · Reply
Aklim72
Aklim72 Jul. 31 at 3:31 PM
$DFNS I would rather take my chances on $SBEV $AIM $CIGL
0 · Reply
Aklim72
Aklim72 Jul. 31 at 3:27 PM
$DFNS Lick your wounds and check $AIM . next $CYCU ?
0 · Reply
Aklim72
Aklim72 Jul. 31 at 3:22 PM
$RDDT check out $AIM .
0 · Reply
igor9040
igor9040 Jul. 31 at 2:53 PM
1 · Reply
Bikinibullshark
Bikinibullshark Jul. 31 at 1:52 PM
$AIM adding
0 · Reply
Leeman02
Leeman02 Jul. 31 at 1:31 AM
$AIM POS
0 · Reply
dingaling123
dingaling123 Jul. 30 at 5:39 PM
$GNS actually let me clarify and expand a bit. The 222 he/she posted about indeed was a (then) all time closing low price of .22, and also the cycle low in 2025 before the run to 1.92. in the post below, I just meant that 0.22 didn't end up being the ALL-TIME closing low. 222 was quite significant for another reason: .22 was the effective price of the investment made in gns earlier this year by the fund linked to the Trumps. The press release said 37 cents for the investment, but they also got free shares in addition to that. So when you calculate the actual break-even price it's 22 cents He posted about 222 in ADVANCE of these events (some of the posts may have been on the $AIM board....he probably posted thousands of times... Possible he posted about the 222 right around when it hit .22,I forget) I also found it interesting that the "15" vision referred to "pieces" being counted. That is yet another reference that could match gns, since the stock price fell apart prior to .15
1 · Reply
TheLionofwallstreet
TheLionofwallstreet Jul. 30 at 4:08 AM
$AIM this is crazy. Only mf space x traded as many shares as this little guppy bio stock. What are the odds. Trillion dollar company and a Company that can barely keep the lights on. Ampligen must be extremely valuable
2 · Reply
ultimatebastos
ultimatebastos Jul. 28 at 1:03 PM
$AIM it’s coming closer
2 · Reply
ultimatebastos
ultimatebastos Jul. 28 at 1:03 PM
$AIM https://www.yahoo.com/news/world/articles/us-ebola-patient-discharged-frankfurt-123338559.html
0 · Reply
ultimatebastos
ultimatebastos Jul. 28 at 1:01 PM
$AIM one day not so far from here the need far AMPLIGEN will be so high. Just disgusting how much money they wast on Ebola instead of saving lives with AMPLIGEN. AIM just doesn’t have the funds to do it alone.
2 · Reply
ultimatebastos
ultimatebastos Jul. 28 at 12:59 PM
$AIM https://www.yahoo.com/news/science/articles/scientists-just-discovered-contagious-cancer-041456091.html
0 · Reply
fatpie68
fatpie68 Jul. 27 at 5:48 PM
$AIM at this point, I'd be happy to see $0.55 per share again. The Dark Pool isn't holding the share price down and on-market Short Interest is easily manageable, but the volume is absolute shit. Once there's news, this stock booms. Nobody is paying attention to this stock until there's a reason to do so.
1 · Reply